Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 155

Sort by

Sort Order Select

Journal Articles

MRD: also for T-lymphoblastic lymphoma

Josep-María Ribera

Blood (2024) 143 (20): 2017–2019.

https://doi.org/10.1182/blood.2024024344

Published: 2024

Journal Articles

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2023-182163

Published: 2023

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2023-186265

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

Development of a Modified Prognostic Index for Adult Patients with Acute Lymphoblastic Leukemia

Eduardo Cerello Chapchap, Ana Luisa Oliveira, Maria Eduarda Alonso Joaquim de Carvalho, Mireia Morgades, Vitor AQ Mauad, Davimar Miranda Maciel Borducchi, Fabio P. S. Santos, Jordi Ribera, Fabio R. Kerbauy, Josep-Maria Ribera, Nelson Hamerschlak

Blood (2023) 142 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2023-184869

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Ajibade Ashaye, Yves Chalandon, Hervé Dombret, Katherine Fazioli, Bingxia Wang, Ibrahim Aldoss, Fei Huang, Jessica T. Leonard, Nora Szabo, Conor McCloskey, Sunita Nair, Mehul Dalal, Meliessa Hennessy, Tammie Yeh, Talha Badar, Hagop Kantarjian, Josep-Maria Ribera, Elias Jabbour

Blood (2023) 142 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2023-179645

Published: 2023

Journal Articles

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 657.

https://doi.org/10.1182/blood-2023-182823

Published: 2023

Journal Articles

Prognostic Factors and Treatment Strategy in Patients with Hodgkin Lymphoma and HIV Infection Treated with ABVD and CART: A Retrospective Study from Spanish Group Geltamo

Maria Huguet, Aleix Méndez, Blanca Sanchez-Gonzalez, Mariana Bastos-Oreiro, Ramon Garcia-Sanz, Samuel Romero, María-Jesús Vidal-Manceñido, Antonio Gutiérrez, Paola Villafuerte Gutierrez, Ana Garcia Noblejas, Gustavo Tapia, Juan-Manuel Sancho, Josep-Maria Ribera, José-Tomás Navarro

Blood (2023) 142 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2023-189756

Published: 2023

Journal Articles

T-ALL in CNS-3 status needs improvement

Josep-Maria Ribera

Blood (2023) 141 (15): 1779–1780.

https://doi.org/10.1182/blood.2022019532

Published: 2023

Journal Articles

JZP458 closes the asparaginase allergy gap

Josep-Maria Ribera

Blood (2023) 141 (7): 685–686.

https://doi.org/10.1182/blood.2022018395

Published: 2023

Journal Articles

A Risk Score for Single-Lumen Peripherally Inserted Central Catheter (PICC)-Related Venous Thrombosis in Cancer Patients Undergoing Ambulatory Chemotherapy

Maria Huguet, Mireia Morgades, Mariana Fernández, Mariana Paola Ferraro, Sviatoslav Chekhun, Rosario Cano, Natalia Calderón, Elisabeth Mompradé, Juan-Manuel Sancho, Josep-Maria Ribera, Jose Tomas Navarro

Blood (2022) 140 (Supplement 1): 8542–8543.

https://doi.org/10.1182/blood-2022-165328

Published: 2022

Journal Articles

Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2022) 140 (Supplement 1): 4848–4850.

https://doi.org/10.1182/blood-2022-166166

Published: 2022

Journal Articles

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Blood (2022) 140 (Supplement 1): 6345–6347.

https://doi.org/10.1182/blood-2022-162159

Published: 2022

Journal Articles

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Jacques-Emmanuel Galimard, Myriam Labopin, Iman Abou Dalle, Bruno Lioure, Johan A. Maertens, Maija Itälä-Remes, Maria Pilar Gallego Hernanz, Gesine Bug, Josep-Maria Ribera, Alain Gadisseur, Christoph Schmid, Xavier Poiré, Manuel Jurado Chacón, Frederic Baron, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 735–736.

https://doi.org/10.1182/blood-2022-162162

Published: 2022

Journal Articles

CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Blood (2022) 140 (1): 38–44.

https://doi.org/10.1182/blood.2021014840

Published: 2022

Includes: Supplemental data

Journal Articles

Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain

Josep-Maria Ribera, Olga Garcia, Pau Montesinos, Rebeca Rodríguez-Veiga, María García-Fortes, Abelardo Barez Garcia, Itziar Oiartzabal, Jose A Gonzalez-Campos, Jose Angel Mendez Sanchez, Maite Zudaire, Lucia Villalon, Oriana López-Godino, Cristina Gil, Ana Vicent, Raquel Saldaña, Marta Valero, Anna Torrent, Jesus Maria Hernández-Rivas

Blood (2021) 138 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2021-148368

Published: 2021

Journal Articles

Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

Domingo Domenech Eva, Juan-Manuel Sancho, Eva González-Barca, Nicholas Kelleher, Marta Rodriguez-Luaces, Jordina Rovira Sole, Silvia Verdesoto, Maite Encuentra, Damir Blazevic, Ana C Oliveira, Lourdes Escoda, Josep-Maria Ribera, Anna Sureda

Blood (2021) 138 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2021-149506

Published: 2021

Journal Articles

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Blood (2021) 138 (Supplement 1): 3486.

https://doi.org/10.1182/blood-2021-148263

Published: 2021

Journal Articles

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Blood (2021) 138 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2021-148361

Published: 2021

NARROW

MRD: also for T-lymphoblastic lymphoma

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Development of a Modified Prognostic Index for Adult Patients with Acute Lymphoblastic Leukemia

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Prognostic Factors and Treatment Strategy in Patients with Hodgkin Lymphoma and HIV Infection Treated with ABVD and CART: A Retrospective Study from Spanish Group Geltamo

T-ALL in CNS-3 status needs improvement

JZP458 closes the asparaginase allergy gap

A Risk Score for Single-Lumen Peripherally Inserted Central Catheter (PICC)-Related Venous Thrombosis in Cancer Patients Undergoing Ambulatory Chemotherapy

Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain

Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only